Wild mushroom intoxications are a recurrent seasonal public health concern, but long-term epidemiological data from Eastern Europe remain limited. This study characterized the long-term epidemiological patterns of wild mushroom intoxications in the Region of Varna, Bulgaria, including temporal trends, demographic characteristics, seasonality, time to hospital presentation, length of hospital stay, and family clustering. We retrospectively reviewed all consecutive patients hospitalized for wild mushroom intoxication at the Clinic of Toxicology, Naval Hospital of Varna, from January 2005 to December 2022. Temporal trends were assessed using the Mann–Kendall test. The sex distribution of cases was tested against an equal distribution using an exact binomial test, sex-specific incidence was compared using incidence rate ratios with sex-specific population denominators, and the χ² test was used for the comparison across study periods. Among 672 patients, sex-specific incidence was almost identical in men and women (8.24 versus 8.10 per 100,000 person-years; IRR 1.02, 95% CI 0.88–1.18), and the most affected age groups were 51–60 years (18.90%) and 61–70 years (16.52%). Annual hospitalizations showed a significant downward trend (Mann–Kendall τ = −0.42, p = 0.017), while the estimated crude hospitalization rate declined from 11.5 per 100,000 person-years in 2005–2010 to 6.3 in 2017–2022. A pronounced seasonal pattern was observed, with cases occurring predominantly in autumn. Most patients presented within six hours of ingestion (83.33%), and two-day hospital stays were most common (69.64%). Forty-seven family clusters were identified. No fatalities or severe complications were recorded. These long-term regional data demonstrate persistent seasonal clustering and predominantly early hospital presentation, while the declining hospitalization burden should not diminish the need for continued surveillance and targeted public health prevention before the autumn foraging season.

Background/Objectives: Triple-negative breast cancer (TNBC) is an aggressive and molecularly heterogeneous breast cancer subtype for which early detection remains clinically important. Circulating non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are being investigated as blood-based biomarkers. This narrative review evaluates the clinical evidence for circulating ncRNAs as liquid-biopsy biomarkers for early TNBC detection, focusing on stage I–II disease, diagnostic performance, comparator selection, and validation. Methods: Peer-reviewed studies published between 2009 and October 2026 were identified primarily through PubMed/MEDLINE searches, supplemented by Google Scholar searches, with particular attention to disease stage, comparator populations, diagnostic performance, and validation status. Results: Among the ncRNA classes reviewed, circulating miRNAs provide the most directly relevant, although still limited, clinical evidence for early-stage TNBC detection, whereas evidence for lncRNAs and circRNAs remains predominantly exploratory and insufficiently validated for early-stage detection. Translation is limited by small, heterogeneous cohorts, analytical variability, and insufficient independent and prospective validation. Conclusions: High diagnostic accuracy in selected cohorts does not establish clinical readiness. Standardized analytical workflows, independent multicenter validation, prospective evaluation in intended-use populations, and integration with imaging and clinical assessment are needed before circulating ncRNA signatures can be considered for clinical use.

Epidermolysis bullosa (EB) is a heterogeneous group of inherited disorders characterised by skin fragility, caused by pathogenic variants in genes encoding structural components of the dermo-epidermal junction. With the advent of next-generation sequencing (NGS), the diagnostic paradigm has shifted from a morphological to a genotype-oriented approach. This review summarises the genetic architecture of EB, the types of mutations and genotype–phenotype relationships, the challenges in interpreting variants of unknown significance (VUS), and therapeutic strategies targeting specific mutational mechanisms, including read-through approaches, exon skipping and genome editing. The role of modifier genes and epigenetic factors in clinical variability is also discussed. The focus is on the translational potential of genomics for personalized therapy in EB. Overall, this review synthesizes the molecular basis of all four major EB types across 16+ classical genes, highlights the paradigm shift where NGS achieves a diagnostic yield exceeding 90%, and critically assesses recent therapeutic milestones—ranging from the first FDA-approved topical gene therapy to precision RNA and genome-editing modalities.